No Data
Lepu Biopharma Renews Procurement Contract With Controlling Shareholder
Lepu Biotech-B (02157.HK) has signed a CDMO service framework agreement with lepu medical technology.
On November 26, Gleam Hill reported that on November 26, 2024, the company entered into a CDMO service framework agreement with lepu medical technology, pursuant to which the company and/or its subsidiaries agreed to provide CDMO technical services and related supporting equipment to lepu medical technology and/or its subsidiaries.
HK stock market anomaly | Xintai Medical (02291) surged more than 30% in early trading. Recently renewed the framework agreement with lepu medical technology. The trade volume may increase year by year in the next three years.
Heartway Medical (02291) surged over 30% in the early session, as of the time of writing, it rose by 30.92%, reaching 22.1 Hong Kong dollars, with a transaction volume of 19.5613 million Hong Kong dollars.
Sinolink Securities: The advantage of "price + medical insurance" brings a breakthrough in CGM volume. Focus on the expansion of medical instruments in the European and American markets.
Europe and the United States occupy more than two-thirds of the global CGM market share, and the average selling price of CGM products is significantly higher compared to domestic prices. If domestic companies can expand overseas markets, they will unlock greater demand and higher price levels.
Lepu Healthcare: Report for the third quarter of 2024
Lepu Medical Technology (300003.SZ) released its performance for the first three quarters, with a net income of 0.803 billion yuan, a decrease of 40.70%.
Lepu Medical Technology (300003.SZ) released its third quarter report for 2024, with revenue for the first three quarters of the company reaching 4...
